Company profile: Tmunity Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered T cell therapies and platforms, developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms to unleash the immunological potential of T cells, treat a wide range of disease indications, and enable control over T cell activation.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tmunity Therapeutics
Hookipa Pharma
HQ: United States
Website
- Description: Provider of arenavirus-based immunotherapies for infectious diseases and cancer, using proprietary TheraT and Vaxwave vector platforms to elicit neutralizing antibodies and T cell responses. Offerings include HB-200 for HPV-associated head and neck cancers, HB-700 for KRAS-mutated cancers, and replicating and non-replicating technologies for oncology and prophylactic immunization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hookipa Pharma company profile →
Adaptate Biotherapeutics
HQ: Canada
Website
- Description: Provider of antibodies designed to modulate gamma delta T cells in situ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptate Biotherapeutics company profile →
Medannex
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical solutions targeting annexin-A1, notably MDX-124—a humanised monoclonal antibody with potential in treating various cancers and autoimmune diseases—and the ATTAINMENT Phase 1b clinical study evaluating the safety, tolerability, and efficacy of MDX-124 in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medannex company profile →
Courier Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions, including a protein therapeutics platform aimed at making cancer immunotherapy safer and more efficacious, with potential in autoimmune and inflammatory diseases; AI-driven drug discovery offerings such as the Opal Computational Platform, Target Discovery, and Logica; and development of investigational therapies like OPL-0401 for diabetic retinopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Courier Therapeutics company profile →
Alligator Bioscience
HQ: Sweden
Website
- Description: Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alligator Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tmunity Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tmunity Therapeutics
2.2 - Growth funds investing in similar companies to Tmunity Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tmunity Therapeutics
4.2 - Public trading comparable groups for Tmunity Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →